PT - JOURNAL ARTICLE AU - Jayaprasad, Niniya AU - Borhade, Priyanka AU - LeBoa, Christopher AU - Date, Kashmira AU - Joshi, Shrikrishna AU - Shimpi, Rahul AU - Andrews, Jason R. AU - Bhatnagar, Pankaj AU - Luby, Stephen P. AU - Hoffman, Seth A. TI - Retrospective Review of Blood Culture-Confirmed Cases of Enteric Fever in Navi Mumbai, India: 2014–2018 AID - 10.1101/2023.05.27.23290637 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.27.23290637 4099 - http://medrxiv.org/content/early/2023/05/28/2023.05.27.23290637.short 4100 - http://medrxiv.org/content/early/2023/05/28/2023.05.27.23290637.full AB - India has one of the highest estimated burdens of enteric fever globally. Prior to implementation of Typbar-TCV® typhoid conjugate vaccine (TCV) in a public sector pediatric immunization campaign in Navi Mumbai, India, we conducted a retrospective review of blood culture-confirmed cases of typhoid and paratyphoid fevers to estimate the local burden of disease. This review included all blood cultures processed at a central microbiology laboratory, serving multiple hospitals, in Navi Mumbai (January 2014–May 2018) that tested positive for either Salmonella Typhi or Salmonella Paratyphi A. Of 40,670 blood cultures analyzed, 1,309 (3.2%) were positive for S. Typhi (1,201 [92%]) or S. Paratyphi A (108 [8%]). Culture positivity was highest in the last months of the dry season (April-June). Our findings indicate a substantial burden of enteric fever in Navi Mumbai and support the importance of TCV immunization campaigns and improved water, sanitation, and hygiene.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Bill and Melinda Gates Foundation Grant #OPP1169264 (PI: Prof. Stephen P. Luby). S.A.H. is supported in part by the National Institutes of Health under the National Institute of Allergy and Infectious Diseases grant T32AI007502, as well as by the Stanford Maternal and Child Health Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local Institutional Review Board approval was not solicited, as the study involved secondary data analysis, while the protocol for this study was approved by the Stanford University IRB (eprotocol #39627). All data provided to investigators were deidentified.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors